DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for vasomotor rhinitis — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleVasomotor rhinitis maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for vasomotor rhinitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
histamine receptor H1 (HRH1) — HRH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hsmdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8YN2 · 2.66 Å · ligand HISTAMINE (HSM). Experimental structure, not a prediction.
What the evidence adds up to
A 2004 review of vasomotor rhinitis found that topical sprays of azelastine, budesonide, and ipratropium are of benefit. The same review noted that electron microscopic evaluation of the nasal mucosa points to a role for neuropeptides and nitric oxide in the pathogenesis, and that objective tests have documented hypoactive sympathetic autonomic dysfunction. A 2020 paper states that vasomotor rhinitis, also called idiopathic rhinitis, is the most common form of chronic rhinitis, affecting 10–20% of the population. It reports that a past respiratory viral infection treated with excessive vasoconstrictor drops triggers onset in most cases.
A 2025 article analyses modern diagnostic and treatment approaches based on clinical observation of two groups of patients. It claims to justify the advantages of modern therapy but does not report any concrete numbers for response rates, survival, or sample sizes. The abstract provides no quantitative efficacy data.
No randomised controlled trial with a placebo arm is described in these abstracts. The evidence for any specific drug remains limited to the 2004 statement that three topical sprays are of benefit, without effect sizes or patient numbers. What is still missing is a properly funded, placebo-controlled trial with objective outcome measures and clear patient stratification, given that the condition is defined largely by exclusion and overlaps with other chronic rhinitis forms.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2004 · 49 citations
Vasomotor rhinitis update
AbstractPURPOSE OF REVIEW: This review was conducted to examine new data on vasomotor rhinitis, a common clinical problem. RECENT FINDINGS: Recent publications highlight advances in the study of the pathophysiology of vasomotor rhinitis. Electron microscopic and ultracytochemical evaluation of the nasal mucosa in vasomotor rhinitis demonstrates an emerging role of neuropeptides and nitric oxide in the pathogenesis of vasomotor rhinitis. Ozone, cigarette smoke, and other environmental factors may trigger neurogenic mechanisms that lead to vasomotor rhinitis. Objective tests have documented the presence of hypoactive sympathetic autonomic dysfunction. Such assessments also suggest autonomic dysfunction as a possible link between vasomotor rhinitis and gastroesophageal reflux disease. Recent publications propose nasal secretory protein analysis as a possible diagnostic tool. Evidence-based review of treatment outcomes shows topical sprays of azelastine, budesonide, and ipratropium to be of benefit in vasomotor rhinitis. SUMMARY: A better understanding of the role of nitric oxide and neuropeptides in the pathogenesis of vasomotor rhinitis has opened new avenues in research, diagnosis, and management. Clinical diagnosis may be aided by the analysis of nasal secretory proteins. Effective treatments include antihistamine, anticholinergics, and steroid nasal sprays.
Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · 2020 · 0 citations
Management of vasomotor rhinitis patients
AbstractThere has been a recent obvious trend towards the increased prevalence of chronic rhinitis – 10-20% of the population experiences this disorder. Vasomotor rhinitis, sometimes also called idiopathic rhinitis, is the indisputable leader among various chronic rhinitis forms (allergic, infectious, atrophic, catarrhal and hypertrophic). The term of vasomotor rhinitis has been the subject of experts' repeated criticism because neurovisceral innervation disorders that underlie this condition are found in almost every form of chronic rhinitis. The main clinical manifestations of vasomotor rhinitis include a feeling of nasal congestion and nasal respiratory obstruction, regular abundant discharge of clear mucus and a feeling of its trickling down the posterior pharyngeal wall. A past respiratory viral infection treated by excessive quantities of vasoconstrictor drops triggers the vasomotor rhinitis onset in most cases.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
TITLE: MODERN APPROACHES TO DIAGNOSIS AND TREATMENT OF VASOMOTOR RHINITIS
AbstractThis article analyzes modern approaches to the diagnosis and treatment of vasomotor rhinitis. The study is based on clinical cases and examines the effectiveness of various diagnostic methods and treatment regimens. The article justifies the advantages of modern therapy based on the results of clinical observation conducted on two groups of patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
